Frankfurt - Delayed Quote EUR

Pareto Bank ASA (8PB.F)

6.98

0.00

(0.00%)

As of 8:02:40 AM GMT+2. Market Open.

Should crypto be part of your retirement? Here's what to know.

The US Labor Department removed guidance discouraging employer-sponsored retirement plans from holding crypto. 401 Financial principal and founder, Tyrone Ross, sits down with Brad Smith to discuss what the change signals about the asset class and outlines what you need to know about investing in crypto for retirement. To watch more expert insights and analysis on the latest market action, check out more Wealth here.

Yahoo Finance Video 1 hour ago

BTC-USD
Gap's Q1 earnings beat overshadowed by up to $300M tariff hit

Gap (GAP) stock is plunging in after-hours trading as investors focus on the retailer's expected tariff hit rather than its first quarter earnings beat. The company's revenue was $3.46 billion, compared to the $3.42 billion expected, while earnings per share (EPS) came in at $0.51, better than the $0.45 analysts estimated. The retailer said it expects the tariff impact to cost up to $150 million in its 2025 operating income and $250–300 million in its gross estimated incremental cost. Gap maintained its full-year outlook but noted that this guidance doesn't reflect potential tariff impacts. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.

Yahoo Finance Video 15 hours ago

GAP
Uber, Tesla robotaxis, Synopsys guidance: Trending Tickers

Uber (UBER) shares slide into negative territory on Thursday amid speculation around Tesla's (TSLA) rollout of robotaxis in Austin, Texas, on June 12. Catch Tesla investor Ross Gerber share his thoughts on Waymo's robotaxi model as compared to Tesla's plans. Synopsys (SNPS) suspends its guidance for its current fiscal third quarter and full-year 2025 as it digests new export controls on shipments to China. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 15 hours ago

TSLA

SNPS

UBER
Costco Stock: Wholesaler Tops Q3 Earnings, Same-Store Sales Miss

Costco stock trades near a buy zone after its Q3 earnings, revenue beat late Thursday. Same-store sales growth fell short of views.

Investor's Business Daily 26 minutes ago

COST
Costco’s $1.50 hot dog still holds — and so does customer loyalty

The $1.50 Costco hot dog — a still point in a turning world, immune to tariffs, inflation, or even Jay Powell — remains the most reliable deal in America. In a time of relentless volatility, the Costco hot dog stands firm.

Quartz 40 minutes ago

COST
OpenAI risks being undercut by cheaper rivals, says star investor

US groups such as OpenAI which are racing to develop artificial intelligence are at risk of being undercut by cheaper rivals such as China’s...

PREMIUM
Financial Times 59 minutes ago

META

OPAI.PVT

SPOT
The Nasdaq Bounces Back: These AI Stocks Could Be the Smartest Buys of the Year

After a painful 20% plunge this spring, the Nasdaq Composite has nearly rebounded all the way back. Investors should take a breath now and look at investing in some of the strongest artificial intelligence (AI) companies. The Nasdaq Composite is only at about breakeven for the year, as of this writing, but it's made a powerful comeback in recent weeks.

Motley Fool 59 minutes ago

NVDA

COMP

DELL
Canopy Growth Reports Fourth Quarter and Fiscal Year 2025 Financial Results

SMITHS FALLS, Ontario, May 30, 2025--Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (Nasdaq: CGC) today announced its financial results for the fourth quarter ended March 31, 2025 ("Q4 FY2025") and the fiscal year ended March 31, 2025 ("FY2025") and the filing of the Company’s Annual Report on Form 10-K for FY2025 (the "Form 10-K"), including the audited consolidated financial statements for FY2025 and the unqualified report thereon of the Company’s independent registere

Business Wire 59 minutes ago

CGC
Social Buzz: Wallstreetbets Stocks Mixed Premarket Friday; Gap to Decline, Dell Technologies to Advance

The most-talked-about stocks in the Reddit subforum Wallstreetbets were mixed hours before Friday's

PREMIUM
MT Newswires 1 hour ago

DELL

RDDT
Trending tickers: Costco, Dell, Ulta, Adidas and Volkswagen

The latest investor updates on stocks that are trending on Friday

Yahoo Finance UK 1 hour ago

^IXIC

^DJI

ULTA
Regeneron shares slide on mixed trial data for smoker's lung drug

(Reuters) -Regeneron shares fell 9% before the bell on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it succeeded in another. Regeneron and partner Sanofi were studying the drug, which some analysts expect could bring in peak sales of as much as $5 billion, for treating chronic obstructive pulmonary disease (COPD). The disease has limited treatment options and the drug, itepekimab, was expected to target a broader patient population compared to Regeneron and Sanofi's blockbuster Dupixent, which is also approved for the condition.

Reuters 1 hour ago

REGN

SNY
Costco Wholesale Fiscal Third-Quarter Comparable Sales Miss Street Views

Costco Wholesale (COST) reported fiscal third-quarter earnings and revenue above market estimates, b

PREMIUM
MT Newswires 1 hour ago

COST
Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug candidate’s late-stage trials.

The Wall Street Journal 1 hour ago

SNY

SNYNF

REGN
TIAN RUIXIANG Holdings Ltd to Acquire Ucare Inc. in US$150 Million All-Stock Deal, Advancing In-Hospital Health Insurance Strategy

BEIJING, May 30, 2025 (GLOBE NEWSWIRE) -- TIAN RUIXIANG Holdings Ltd (Nasdaq: TIRX) (the "Company" or “TRX”), a China-based insurance broker, today announced plans to acquire 100% of issued and outstanding shares of Ucare Inc. (“Ucare”), the sole operator of China’s only cloud-based AI-driven hospital and health insurance risk management platform, in an all-share deal valued at US$150 million. This strategic move aims to unlock new growth opportunities in the health insurance segment. The Compan

GlobeNewswire 1 hour ago

TIRX
The Zacks Analyst Blog Highlights Costco, The Gap, Dell Technologies, Marvell Technology and Ulta Beauty

Costco, Dell, Marvell and Ulta beat estimates, while Gap tumbles 17% despite a Q1 beat.

Zacks 1 hour ago

MRVL

DELL

COST
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

MIAMI, May 30, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab, successfully met the progression-free survival (PFS) primary endpoint and showed a positive trend in the other primary endpoint, overall survival (OS).

Business Wire 1 hour ago

SMMT
Delivering Success: DoorDash's Approach to Underpenetrated Markets

The success of Dash's network effect is critical to maintaining critical mass, which is the tipping point at which network effects become self-maintaining.

GuruFocus.com 2 hours ago

UBER
This Company's CEO Said It Wants to Become the Nvidia of Quantum Computing. Should You Buy the Stock Now?

It's a bold statement, but if he's right, the stock would generate life-changing investment returns.

Motley Fool 3 hours ago

NVDA

IONQ-WS
Bitcoin Price Falls. The House Just Introduced a New Crypto Bill.

Bitcoin price slipped even as major developments for the crypto industry look to be underway in the U.S.

Barrons.com 3 hours ago

^GSPC

BTC-USD

ETH-USD
Sanofi, Regeneron shares nosedive after mixed Itepekimab results

Investing.com -- Shares in Sanofi (EPA:SASY) (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) fell Friday after the pharmaceutical giants reported mixed results from two phase 3 trials of their investigational chronic obstructive pulmonary disease (COPD) treatment, Itepekimab.

Investing.com 3 hours ago

SNY

REGN

Performance Overview

Return	8PB.F	OBX Total Return Index (OBX.OL)
YTD	+207.53%	+12.19%
1-Year	+246.96%	+11.74%
3-Year	+6,622.30%	+27.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pareto Bank ASA (8PB.F)

Related News

Should crypto be part of your retirement? Here's what to know.

Gap's Q1 earnings beat overshadowed by up to $300M tariff hit

Uber, Tesla robotaxis, Synopsys guidance: Trending Tickers

Costco Stock: Wholesaler Tops Q3 Earnings, Same-Store Sales Miss

Costco’s $1.50 hot dog still holds — and so does customer loyalty

OpenAI risks being undercut by cheaper rivals, says star investor

The Nasdaq Bounces Back: These AI Stocks Could Be the Smartest Buys of the Year

Canopy Growth Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Social Buzz: Wallstreetbets Stocks Mixed Premarket Friday; Gap to Decline, Dell Technologies to Advance

Trending tickers: Costco, Dell, Ulta, Adidas and Volkswagen

Regeneron shares slide on mixed trial data for smoker's lung drug

Costco Wholesale Fiscal Third-Quarter Comparable Sales Miss Street Views

Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials

TIAN RUIXIANG Holdings Ltd to Acquire Ucare Inc. in US$150 Million All-Stock Deal, Advancing In-Hospital Health Insurance Strategy

The Zacks Analyst Blog Highlights Costco, The Gap, Dell Technologies, Marvell Technology and Ulta Beauty

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

Delivering Success: DoorDash's Approach to Underpenetrated Markets

This Company's CEO Said It Wants to Become the Nvidia of Quantum Computing. Should You Buy the Stock Now?

Bitcoin Price Falls. The House Just Introduced a New Crypto Bill.

Sanofi, Regeneron shares nosedive after mixed Itepekimab results

Performance Overview